Release and Stability Testing Programs for a Novel Virus-Like Particle Vaccine - Release testing involves both standard potency assays and unique assays (particle size, NA activity) developed to

ADVERTISEMENT

Release and Stability Testing Programs for a Novel Virus-Like Particle Vaccine
Release testing involves both standard potency assays and unique assays (particle size, NA activity) developed to ensure the physical, chemical, and biological stability of this type of vaccine.


BioPharm International Supplements


Novavax Recombinant VLP Vaccines

Through the use of a recombinant baculovirus–insect host cell system, Novavax has developed a platform technology to produce VLP vaccines to multiple targets including influenza, SARS, and HIV. Influenza VLPs have been biochemically characterized and GMP-produced materials have been tested in five clinical trials, with a total of more than 5,000 subjects.1


Figure 1. Recombinant influenza virus-like particles (VLPs) and pleomorphic spherical particles
The establishment of a recombinant baculovirus containing the influenza genes for the hemagglutinin (HA) and neuraminidase proteins (NA) together with the gene for Matrix (M1) protein is the key step in this process.2 The HA and NA genes are obtained from viral RNA of relevant circulating seasonal or pandemic influenza strains by molecular means from isolated RNA. Alternately, they can be chemically synthesized and then, through a series of cloning steps, placed in a single plasmid (bacmid) under the control of baculovirus-specific transcription initiation and translation elements along with a constant M1 gene sequence shown to allow enhanced VLP formation. Transfection of the bacmid into Spodoptera frugiperda (Sf9) insect cells generates baculoviruses that encode and express the three influenza genes. Baculovirus stocks are further amplified on Sf9 cells to generate master and working virus stocks. Infection of Sf9 cells with the recombinant baculovirus allows expression of the HA, NA, and M1 proteins which form pleomorphic spherical membrane-containing particles with HA and NA protein spikes on their surface and an M1 core. An example of an influenza VLP is shown in Figure 1. These particles are released into the cell culture supernatant and then purified, resulting in the VLP vaccine. The membrane nature of these particles is different from currently licensed VLP vaccines and presents purification and characterization challenges.

VLP Production and Purification

Production and purification of influenza VLPs has been performed for Phase 2 clinical trial materials. Sf9 insect cells from a working cell bank are amplified to seed a 100-L disposable wave bioreactor cell culture, which is then infected with a master baculovirus seed. During harvest, cells are removed by tangential flow filtration (TFF) and the filtrate is concentrated and diafiltered to remove media components and cell debris.


Figure 2. Purification of virus-like particles (VLPs) using an ion exchange (IEX) column. Host cell contaminants—baculovirus (BV), DNA, and RNA—bind, whereas VLPs flow through.
VLPs are separated from baculovirus (BV) particles and contaminating RNA and DNA using a flow-through ion exchange (IEX) chromatography step in which BV, RNA, and DNA are bound to the column while VLP is allowed to flow through (Figure 2). This process step takes advantage of the charge difference between BV and VLP; BV is highly negatively charged by virtue of its DNA content, whereas VLP lacks this charge given the absence of DNA. Allowing VLP to be separated from BV without binding to the column matrix eliminates the need to modify this purification step from season to season in response to changes in the HA protein.


Figure 3. Residual host contaminants are removed by size exclusion chromatography.
Residual BV is inactivated by treatment with beta-propiolactone (BPL) and residual host contaminants are removed by size exclusion chromatography (SEC), as shown in Figure 3. The VLP preparation is sterile filtered to produce the bulk vaccine.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here